Press Releases

Webcast
Q4 2017 Geron Earnings Conference Call
Mar 19, 2018 at 8:30 AM EDT
Webcast Presentation

Q4 2017 Geron Earnings Conference Call
Mar 19, 2018 at 8:30 AM EDT
Webcast
Geron at 17th Annual Needham Healthcare Conference
Mar 27, 2018 at 4:00 PM EDT
Webcast Presentation

Geron at 17th Annual Needham Healthcare Conference
Mar 27, 2018 at 4:00 PM EDT
Date Title and Summary  
Toggle Summary Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
MENLO PARK, Calif. , Dec. 06, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced four presentations of exploratory preclinical and clinical data related to the imetelstat program at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego,
Toggle Summary Geron Announces November Investor Conference Presentation Webcasts
MENLO PARK, Calif. , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett , M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences: Stifel 2016 Healthcare Conference in New York at 9:30 a.m.
Toggle Summary Geron Corporation Reports Third Quarter 2016 Financial Results and Recent Events
Conference Call Scheduled for 4:30 p.m. EDT Today, November 3 MENLO PARK, Calif. , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and nine months ended September 30, 2016 and recent events.
Toggle Summary Geron Announces Presentations at American Society of Hematology Annual Meeting
MENLO PARK, Calif. , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that four abstracts related to the imetelstat program have been accepted for presentation at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego,
Toggle Summary Geron Announces Conference Call to Discuss Third Quarter 2016 Financial Results
MENLO PARK, Calif. , Oct. 26, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2016 , on Thursday, November 3, 2016 , after the market close. Geron’s management will also host a conference call for analysts and
Toggle Summary Geron Provides Update on Imetelstat Trials Being Conducted by Janssen
Conference Call Scheduled for 8:00 a.m. EDT Today, September 12 MENLO PARK, Calif. , Sept. 12, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today provided updates on the clinical trials being conducted by Janssen Research & Development, LLC , of the telomerase inhibitor imetelstat.
Toggle Summary Geron Announces Conference Call on September 12 at 8:00 A.M. Eastern Time
MENLO PARK, Calif. , Sept. 11, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will host a conference call on September 12, 2016 , at 8:00 a.m. Eastern Time to provide an update on the imetelstat Phase 2 trial in myelofibrosis and Phase 2/3 trial in myelodysplastic syndromes.
Toggle Summary Geron Corporation Reports Second Quarter 2016 Financial Results and Recent Events
Conference Call Scheduled for 4:30 p.m. EDT Today, August 3 MENLO PARK, Calif. , Aug. 03, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and six months ended June 30, 2016 and recent events. For the second quarter of 2016, the company
Toggle Summary Geron Announces Conference Call to Discuss Second Quarter 2016 Financial Results
MENLO PARK, Calif. , July 27, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the second quarter ended June 30, 2016 , on Wednesday, August 3, 2016 , after the market close. Geron’s management will also host a conference call for analysts and
Toggle Summary Geron Announces Issuance of U.S. Patents Related to Imetelstat
MENLO PARK, Calif. , July 13, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the recent issuance of three U.S. patents related to the company’s telomerase inhibitor, imetelstat. The first patent, U.S. 9 ,375,485, has claims covering the use of telomerase inhibitor